 MediWound Ltd. MDWD the Company, a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today provided an update on certain impacts of the COVID-19 pandemic on its business operations and clinical programs. At the same time, the Company is working to ensure that healthcare providers and patients have uninterrupted access to our commercial and products under development. The Company has instituted a global remote work policy and is now leveraging virtual tools and digital communication technologies to continue important interactions with its employees, healthcare professionals, patients and other stakeholders. 